 |
|
| |
|
This
page contains all corrections published in recent Medical Letter
publications (newsletter, handbooks, software).
|
|
| 2007 |
|
| Hand Hygiene and CDAD |
|
| The Medical Letter • Volume 49, January 29, 2007 |
| Clarification: In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.” One reader pointed out that alcohol based products do eradicate some C. difficile spores and have been invaluable against other pathogens. More… |
|
 View the updated online version of this article. |
|
Panitumumab (Vectibix) for Metastatic Colorectal Cancer |
|
| The Medical Letter • Volume 49, April 23, 2007 |
| Correction: Corrected Clinical Studies, Other Cancers section, p. 35: Panitumumab dosage from 25 mg/kg to 2.5 mg/kg. |
|
| View the updated online version of this article. |
| |
| Choice of Antibacterial Drugs |
| |
|
Treatment Guidelines
• Volume 5, May 2007 |
Corrections:
1) Correction on p. 36, HAP section, last paragraph, top of 2nd column: changed from (polymixin B) to (polymyxin E).
2) Correction on p. 46-47, Cefdinir dosage: adult dosage should be 300 mg q12h; pediatric dosage should be 7 mg/kg q12h or 14 mg/kg q24h. Amoxicillin dosage: adult dosage should be 500 mg q8h; pediatric dosage should be 6.6-13.3 mg/kg q8h or 15 mg/kg q12h. Amoxicillin/clavulanate dosage: adult dosage should be 875 mg q12h; pediatric dosage should be 6.6-13.3 mg/kg q8h or 15 mg/kg q12h.
3) Correction on p. 48, Xifaxanis not available generically.
|
| |
|
View the corrected online version
of this article. |
| |
| Drugs for Non-HIV Viral Infections |
| |
|
Treatment Guidelines
• Volume 5, July 2007 |
| Correction: In the drugs for Hepatitis B and C, Tenofovir (Viread) and Emtricitabine (Emtriva) section, p. 68, the Resistance paragraph pertains to HIV, not Hepatitis B. That paragraph has been deleted from the online version.
|
| |
|
View the corrected online version
of this article. |
|
Lyme Disease |
|
| The Medical Letter • Volume 49, June 18, 2007 |
| Correction: The PR interval in the table on page 50 and at the top of the first column of text on page 51 should be 300 milliseconds, not 30. Also, in the first paragraph of the article, Minnesota (MN), not Michigan (MI), is one of the 12 states in 2005 that reported about 95% of all the Lyme disease in the US. |
|
| View the updated online version of this article. |
| |
| Drugs for Allergic Disorders |
| |
|
Treatment Guidelines
• Volume 5, August 2007 |
Corrections: Pediatric age range was omitted in the tables for levocetirizine (Xyzal) and ketorolac (Acular).
1) p. 72 (table): (Xyzal) is for 6-11 years.
2) p. 75 (table): (Acular) is for ≥3 yrs.
|
| |
|
View the corrected online version
of this article. |
|
Resperate for Hypertension |
|
| The Medical Letter • Volume 49, July 2, 2007 |
| Correction: The second sentence in the Resperate for Hypertension article ("The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.") should have been omitted. It would apply to a Class I device, but the FDA has classified Resperate as a Class II device. |
|
| View the updated online version of this article. |
|
A New Sunscreen Agent |
|
| The Medical Letter • Volume 49, May 21, 2007 |
| Addendum: An article on sunscreens in the May 21 issue of The Medical Letter included a statement that if sunscreens and the insect repellent DEET are used together, DEET should be applied first to avoid decreasing the effectiveness of the sunscreen. However, a recent in vitro study in human skin found that sunscreen increases absorption of DEET, especially when DEET is applied first (T Wang and X Gu. J Pharm Pharm Sci 2007;10:17). Whether this practice could cause clinical toxicity is unclear. Some travel experts recommend applying sunscreen first. |
|
Low Dose Transdermal Estrogens |
|
| The Medical Letter • Volume 49, August 27, 2007 |
| Correction: In the first paragraph, last sentence, EstroGel (Ascend Therapeutics) has has been available in Europe since 1976 (not Elestrin). |
|
| View the updated online version of this article. |
|
Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures |
|
| The Medical Letter • Volume 49, December 3, 2007 |
| Correction: On page 100 under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline. |
|
| View the updated online version of this article. |
|
| 2006 |
|
| Statins for High-Risk Patients without Heart Disease or High Cholesterol |
|
| The Medical Letter • Volume 48, January 2, 2006 |
| Correction: In the clinical studies table on page 2, the footnote should have read: In the ASCOT trial (not ASCOT-LLA), 19,342 patients were randomized ..... lipid-lowering arm (ASCOT-LLA). |
|
| View the corrected online version of this article. |
| |
| A Combination of Oxycodone and Ibuprofen (Combunox) for Pain |
|
| The Medical Letter • Volume 48, January 2, 2006 |
| Addendum: The conclusion of the article on Combunox (Med Lett Drugs Ther 2006; 48:4) mentioned the possibility of taking 2 tablets at one time of Vicoprofen, which would contain 15 mg of hydrocodone. That dose has not been approved by the FDA. |
| |
| Coenzyme Q10 |
|
| The Medical Letter • Volume 48, February 27, 2006 |
| Correction: In the clinical studies section on page 19 in the
Coenzyme Q10 article (February 27, 2006; issue 1229), the last sentence of the Parkinson’s disease paragraph should read: The difference between placebo and 1200 mg/day was statistically significant, but
none of the doses lengthened (not shortened) the time to requiring treatment with levodopa. |
|
| View the corrected online version of this article. |
| |
| Influenza Vaccine 2006-2007 |
|
| The Medical Letter • Volume 48, October 9, 2006 |
| Addendum: Since the publication of our article on influenza vaccine (October 9, 2006), a fourth inactivated vaccine (FluLaval – GlaxoSmithKline) has been approved by the FDA for use in people ≥18 years old. It is sold in 5-mL multi-dose vials. Each 0.5-mL intramuscular dose contains 25 mcg of mercury. |
| |
| Three New Oral Contraceptives |
|
| The Medical Letter • Volume 48, September 25, 2006 |
| Correction: In issue 1244, September 25, 2006, in the table at the bottom of page 77, the manufacturer of Loestrin 24 Fe is Warner Chilcott, not Duramed. |
|
| View the corrected online version of this article. |
| |
| 2005 |
| |
| Apomorphine (Apokyn) |
| |
| The Medical Letter • Volume 47, January 17, 2005 |
| Correction: In the interactions section on page 7 in the apomorphine article, the first sentence should read, "Apomorphine is contraindicated with ondansetron (Zofran, and others) and other serotonin receptor antagonists..." (not agonists).
|
| |
|
View the corrected online version
of this article. |
| |
| NSAID Alternatives |
| |
| The Medical Letter • Volume 47, January 17, 2005 |
| Addendum: In our January 17 issue, a short article on NSAID alternatives mentioned that tramadol (Ultram, and others), a weak opioid analgesic, could be helpful for some patients. A few readers have commented that we should have said something about its drawbacks. The need for slow titration in dosage limits the drug's use for treatment of acute pain. Seizures have been reported with tramadol; patients taking an antidepressant or an antipsychotic drug may be at increased risk. Tramadol is not a controlled substance, but psychological and physical dependence have occurred.
|
| |
| Drugs for Lipids |
| |
|
Treatment Guidelines
• Volume 3, March 2005 |
| Correction: In the Lipids article on page 16, results of the A to Z Trial (in the Very High Risk paragraph) should have said "between 4 and 24 months" rather than "after 24 months" when describing reduction of major cardiovascular events plus stroke with intense simvastatin treatment.
|
| |
|
View the corrected online version
of this article. |
| |
| Drugs for Non-HIV Viral Infections |
| |
|
Treatment Guidelines
• Volume 3, April 2005 |
| Correction: The Treatment Guidelines
article on Drugs for Non-HIV Viral Infections (Vol. 3, April 2005) has an error on page 32. Footnote 4 in the table should read: "Immunoprophylaxis with IM palivizumab," not IV. |
| |
|
View the corrected online version
of this article. |
| |
| Menactra Supply |
| |
| The Medical Letter • Volume 47, April 11, 2005 |
| Addendum: The recent Medical Letter article on the new conjugated meningococcal vaccine (April 11, 2005) stated that there was a shortage of the vaccine. The manufacturer says that so far there is no shortage; the supply exceeds the demand.
|
| |
| Vitamin Supplements |
| |
| The Medical Letter • Volume 47, July 18, 2005 |
| Addendum: The recent Medical Letter article on Vitamin Supplements (July 18, 2005; issue 1213) stated in its conclusion that there is no convincing evidence that taking supplements of vitamin C prevents any disease. We should have added, "...except scurvy."
|
| |
| Colonoscopy Preparations |
| |
| The Medical Letter • Volume 47, July 4, 2005 |
| Addendum: Since the publication of our article on colonoscopy preparations (July 4, 2005; issue 1212), which compared polyethylene glycol electrolyte solutions (GoLytely, and others) with sodium phosphate (Fleet Phospho-Soda, and others), some readers have told us that we should have included a combination of a magnesium citrate solution with bisacodyl tablets (Evac-Q-Kwik, and others) as an alternative. In one study, such a preparation offered better cleansing and patient tolerance than a sodium phosphate regimen (M Delegge and R Kaplan. Efficacy of bowel preparation with the use of a prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a clear liquid diet with a standard sodium phosphate cathartic. Aliment Pharmacol Ther 2005; 21:1491).
|
| |
| 2004 |
| |
| Alfuzosin (Uroxatral) |
| |
| The Medical Letter • Volume 46, January 5, 2004 |
| Addendum: The table in the article on alfuzosin for treatment of benign prostatic hyperplasia (January 5, 2004, vol. 46, p.1) omitted the generic alpha1-blockers. The complete table with prices updated to December 2003 is now in the issue. |
| |
|
View the corrected online version
of this article. |
| |
| Drugs for Parkinson's Disease |
| |
|
Treatment Guidelines
• Volume 2, June 2004 |
| Correction: The Treatment Guidelines
article on Drugs for Parkinson's Disease (Vol. 2, June 2004) has an error on page 43. Orthostatic hypotension (not hypertension) is an adverse effect of apomorphine. |
| |
|
View the corrected online version
of this article. |
| |
| Telithromycin (Ketek) for Respiratory Infections |
| |
|
The Medical Letter
• Volume 46, August 16, 2004 |
| Correction: In the table on page 66, the daily dosage of erythromycin should be 250-500 mg qid (not bid). Also, in the Canadian edition, the cost of telithromycin (Ketek) should be $65.52 (not $32.76). |
| |
|
View the corrected online version
of this article: U.S. Canadian |
| |
| Generic Levothyroxine |
| |
|
The Medical Letters
• Volume 46, September 27, 2004 |
| Addendum: In preparing the Canadian edition of the September 27 issue, we noticed that the Canadian price for Synthroid is $6.40 (US $4.92) for 100 100-mcg tablets, compared to $52.70 in the US, an extraordinary 10-fold difference. Synthroid may have been reformulated in the US after the FDA in 1997 required all manufacturers of levothyroxine to file new drug applications because of concerns about the potency of various formulations, including Synthroid. The FDA approved Synthroid in 2002. Health Canada found no indication of a quality concern with Synthroid tablets in 2002, but in July 2004 it announced that levothyroxine will be regulated as a new drug there as well, and additional evidence of safety, efficacy and quality may be required. |
| |
|
View the corrected online version
of this article. |
| |
| 2003 |
| |
| Drugs
for Rheumatoid Arthritis |
| |
| Treatment
Guidelines • Volume 1, January 2003 |
| Correction: The Treatment Guidelines
article on Drugs for Rheumatoid Arthritis (Vol. 1, January
2003) has an error on page 28. The paragraph on pregnancy should read: |
| |
| Use of NSAIDs during pregnancy has been
associated with premature closure of the ductus arteriosus in the
fetus and persistent pulmonary hypertension in the newborn (MA Alano
et al, Pediatrics 2001; 107:519). These effects appear to be uncommon
if the NSAID is stopped 6 to 8 weeks before delivery (M Ostensen and
H Ostensen, J Rheumatol 1996; 23:1045). |
| |
|
View the corrected online version
of this article. |
| |
| Smallpox
Vaccination |
| |
|
The Medical Letter
• Volume 45, January 6, 2003 |
| Clarification: The single sentence
on vaccination site care in our article Smallpox Vaccination
(Vol. 45, page 2) needs clarification. In the past, the vaccination
site was generally left uncovered, but current plans for Phase I call
for it to be covered with both gauze to absorb liquid and a semipermeable
membrane such as an Opsite dressing to prevent spread of the virus. |
| |
|
View the corrected online version
of this article. |
| |
| Adverse
Drug Interactions Program and Handbook
of Adverse Drug Interactions |
| |
| Correction: In the February 2003 update of the Adverse Drug Interactions Program and in the Handbook of Adverse Drug Interactions 2003, the potentially lethal interaction between selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) was inadvertently omitted for citalopram (Celexa) and escitalopram (Lexapro). This interaction could occur with any SSRI. |
| |
| FluMist: An Intranasal Live Influenza Vaccine |
| |
|
The Medical Letter
• Volume 45, August 18, 2003 |
| Addendum: FluMist Storage: The storage requirements for FluMist, the intranasal live-attenuated influenza vaccine (Medical Letter 2003; 45:65) have changed. New data have shown that frost-free freezers are appropriate for storage for at least 3 months, without need for a freezer-box insert. |
| |
|
View the corrected online version
of this article. |
| |
| Growth Hormone for Normal Short Children |
| |
|
The Medical Letter
• Volume 45, November 10, 2003 |
| Correction: Cost of Genotropin: A reader has pointed out that The Medical Letter article on Growth Hormone for Normal Short Children (Medical Letter 2003, volume 45, page 89) underestimated the annual cost of Genotropin (Pfizer) because the Genotropin Pen 5 Delivery Device that is used with 5.8-mg cartridges is designed to deliver 5.0 mg of the drug. The annual cost of Genotropin in our November 10, 2003 article should have been $22,625. |
| |
|
View the corrected online version
of this article. |
| |
| Efalizumab (Raptiva) for Treatment of Psoriasis |
| |
|
The Medical Letter
• Volume 45, December 8, 2003 |
| Two Corrections: In the issue of December 8, 2003, volume 45, on page 97 in the table, infliximab (Remicade) is given at weeks 0, 2 and 6 (not days). On page 98, patients in the Leonardi study were treated with etanercept 50 mg twice a week, not once. |
| |
|
View the corrected online version
of this article. |
| |
| Drugs
for Treatment of Non-HIV Viral Infections |
| |
| The
Medical Letter
• Volume 44,
February 4, 2002 |
| Correction: In the table on Drugs
of Treatment for Viral Infections (Volume 44, page 10, February
4, 2002), the dosage of valacyclovir for treatment of recurrence of
genital herpes should be 500 mg PO b.i.d. (not 1 x/day) x 3 days,
and the cost should be $21.70. |
| |
|
View the corrected online version
of this article. |
| |
| Drugs
for Parasitic Infections |
| |
| The
Handbook of Antimicrobial Therapy •
April, 2002 |
| Correction: In the article on Drugs
for Parasitic Infections and in The Medical Letter Handbook
of Antimicrobial Therapy, 16th edition on page 130, the pediatric
dosage of doxycyline (combined with quinine sulfate) for treatment
of chloroquine-resistant P. falciparum malaria should be 2
mg/kg/d x 7d. |
| |
|
View the corrected online version
of this article. |
|
|
